Introduction: The Sinopharm BBIBP-CorV vaccine produces a variety of cutaneous adverse effects. Scleromyxedema is a mucinous connective tissue disorder that causes skin thickness and sclerodermoid changes. According to our findings, this is the first case of scleromyxedema induced by the Sinopharm immunization.
Case Description: We discuss the case of a 75-year-old woman who acquired progressive thickening of the skin in her limbs and trunk after getting the Sinopharm vaccination. Examination, laboratory testing, and a biopsy were used to verify scleromyxedema diagnosis. Intravenous immunoglobulins, mycophenolate mofetil, and prednisolone were used in the treatment of the patient. The outcomes from the 4-month follow-up were reassuring.
Conclusion: This study emphasizes the need of considering scleromyxedema as a connective tissue pathology in patients who have recently received Sinopharm vaccine and have similar cutaneous signs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242695 | PMC |
| http://dx.doi.org/10.1177/23971983221107321 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing the protection of heterologous booster of inhaled Ad5-nCoV vaccine and hybrid immunity against Omicron BA.5 infection: a cohort study of hospital staff in China.
BMC Infect Dis
December 2024
School of Public Health, Tianjin Medical University, Tianjin, 300070, China.
Background: After the exit "zero-COVID" strategy in mainland China by the end of 2022, a large-scale COVID-19 outbreak seeded by Omicron variants occurred. An inhaled adenovirus type-5 vector-based (i.e.
View Article and Find Full Text PDFDe novo myasthenia gravis in a patient with malignant melanoma after concurrent SARS-CoV-2 vaccination and immune checkpoint inhibitor therapy: Case report and literature review.
eNeurologicalSci
December 2024
ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- * Due to the COVID-19 pandemic, cancer patients were prioritized for vaccination, despite not being included in vaccine trials, raising concerns about potential autoimmune responses when vaccinated while on ICIs.
- * A case study is presented of a melanoma patient who developed fatal myasthenia gravis after receiving the inactivated Sinopharm COVID-19 vaccine along with pembrolizumab, highlighting safety concerns and the need for further research on vaccines and irAEs in ICI-treated patients.
Evaluation of BBIBP-CorV Sinopharm COVID-19 vaccine effectiveness in Sri Lanka: a test-negative case control study.
BMJ Open
November 2024
State Pharmaceuticals Corporation of Sri Lanka, Colombo, Sri Lanka.
Objectives: There is limited research on real-world effectiveness of BBIBP-CorV Sinopharm COVID-19 vaccine. This study evaluated real-world effectiveness of Sinopharm vaccine in Sri Lanka by assessing absolute vaccine efficacy.
Design And Setting: A retrospective test-negative case-control study was conducted at ten large government hospitals across the country.
Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.
Front Immunol
November 2024
Center for Clinical and Nutritional Chemistry, School of Chemistry, University of the Punjab, Lahore, Pakistan.
Article Synopsis
- The study investigates the effects of heterologous (different) and homologous (same) COVID-19 vaccine booster doses in healthy adults in Pakistan, focusing on immune responses nine months post-vaccination.
- A total of 173 participants aged 18-25 received either Sinopharm BBIBP-CorV or Pfizer-BioNTech vaccines, with antibody levels measured to compare immune responses.
- Results show that the Pfizer group had significantly higher IgG antibody levels compared to the Sinopharm group, suggesting that a third Pfizer dose after two Sinopharm doses enhances overall immune response, with no significant differences between genders.
Analysis of immunological and biochemical parameters after booster dose vaccination using protein-based and inactivated virus vaccine for safety.
Heliyon
November 2024
Department of Research and Development, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.
Introduction: Heterologous vaccines enhance the immune response to new variants and allow flexibility in booster administration when the original vaccine is unavailable. Studies show that heterologous boosters can generate comparable or superior antibody responses compared to homologous boosters. Considering rare side effects is essential in evaluating COVID-19 vaccines, especially those associated with ChAdOx1-S (AstraZeneca) and Ad26.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!